S&P 500 7,459.94 â–ŧ 73.83 (-0.98%) DOW 52,169.10 â–ŧ 383.87 (-0.73%) NASDAQ 25,535.42 â–ŧ 346.53 (-1.34%) US Markets Closed â€ĸ 12:26 AM ET

TVRD

Tvardi Therapeutics, Inc.

Price Chart
Latest Quote

$3.20

+0.12 (+3.90%)
Current Price
Previous Close $3.08
Open $3.00
Day High $3.45
Day Low $2.92
Volume 965,160
Fetched: 2026-07-18T04:26:38
Stock Information
Shares Outstanding 9.38M
Total Debt $174K
Cash Equivalents $24.98M
Net Income $-15.44M
Sector Healthcare
Industry Biotechnology
Market Cap $30.02M
EPS (TTM) $-0.28
Exchange NCM
🌐 Visit Website
📊 Comprehensive Analysis
Company Data
Enterprise Value$5.21M
Income$-15.44M
Book/sh$1.55
Cash/sh$2.66
Employees12
Financial Ratios
Quick Ratio2.22
Current Ratio2.25
Debt/Eq1.20
Returns & Margins
ROA-68.64%
Ownership
Insider Ownership34.64%
Institutional Ownership28.93%
Insider & Institutional transactions data not available
Valuation Ratios
Forward P/E-1.17
P/B2.07
Analyst Data
Recommendationbuy
Target Price$9.75
Technical Indicators
SMA20$2.73
SMA50$3.11
SMA200$5.41
RSI64.31
ATR0.7321
Shares Float5.67M
Short Float5.44%
Short Ratio1.36
Rel Volume0.14
Performance History
Week-2.44%
Month+21.67%
Quarter-0.62%
6 Months-30.89%
YTD-21.57%
Year-85.93%
3 Years-96.80%
5 Years-99.36%
10 Years-98.22%
Stock Score: ⭐ Premium
Based on debt, profitability, growth, and cash flow metrics
⭐ Premium Feature

Sign up for free to view detailed scoring breakdown — premium is free during our trial period!

Recent Price History
Date Close Volume
2026-07-17 $3.20 971,700
2026-07-16 $3.08 1,716,900
2026-07-15 $2.93 976,600
2026-07-14 $3.10 1,659,000
2026-07-13 $3.31 2,242,000
2026-07-10 $3.28 2,765,200
2026-07-09 $3.80 7,485,600
2026-07-08 $5.00 39,153,000
2026-07-07 $3.10 70,894,200
2026-07-06 $2.01 74,900
2026-07-02 $2.02 112,100
2026-07-01 $1.95 168,200
2026-06-30 $1.90 409,200
2026-06-29 $1.91 4,328,700
2026-06-26 $1.50 1,997,900
2026-06-25 $2.36 52,600
2026-06-24 $2.35 59,200
2026-06-23 $2.42 58,800
2026-06-22 $2.68 73,500
2026-06-18 $2.63 103,500
About Tvardi Therapeutics, Inc.

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.

📰 Latest News
TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know
Zacks â€ĸ 2026-07-09T14:52:00Z
Article thumbnail
Sector Update: Healthcare Stocks Lower Wednesday Afternoon
MT Newswires â€ĸ 2026-07-08T17:48:15Z
Top Midday Gainers
MT Newswires â€ĸ 2026-07-08T17:26:02Z
Sector Update: Health Care Stocks Fall Late Afternoon
MT Newswires â€ĸ 2026-04-20T19:55:23Z
We're Keeping An Eye On Tvardi Therapeutics' (NASDAQ:TVRD) Cash Burn Rate
Simply Wall St. â€ĸ 2026-02-07T13:48:02Z
Article thumbnail
Tvardi (TVRD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Zacks â€ĸ 2025-11-18T14:55:02Z
Article thumbnail
Tvardi: Q3 Earnings Snapshot
Associated Press Finance â€ĸ 2025-11-13T21:08:55Z
Here's Why Tvardi (TVRD) Is a Great 'Buy the Bottom' Stock Now
Zacks â€ĸ 2025-10-28T13:55:02Z
Article thumbnail
Down 83.0% in 4 Weeks, Here's Why Tvardi (TVRD) Looks Ripe for a Turnaround
Zacks â€ĸ 2025-10-16T13:35:02Z
Article thumbnail
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals
Zacks â€ĸ 2025-10-14T15:24:00Z
Article thumbnail
Period:
Income Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Revenue
Total Revenue $0 $0 $0 $0
Operating Revenue $0 $0 $0 $0
Expenses
Total Expenses $26,748,000 $28,107,000 $18,665,000 $21,193,000
Other Income Expense $7,159,000 $-2,037,000 - -
Other Non Operating Income Expenses $7,159,000 $-2,037,000 - -
Net Non Operating Interest Income Expense $1,375,000 $747,000 $1,318,000 $651,000
Operating Expense $26,748,000 $28,107,000 $18,665,000 $21,193,000
General And Administrative Expense $8,737,000 $4,457,000 $2,799,000 $2,727,000
Interest Expense - - $0 $3,000
Interest Expense Non Operating - - $0 $3,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest $-18,214,000 $-29,397,000 $-17,347,000 $-20,542,000
Net Interest Income $1,375,000 $747,000 $1,318,000 $651,000
Interest Income $1,375,000 $747,000 $1,318,000 $654,000
Normalized Income $-18,214,000 $-29,397,000 $-17,347,000 $-20,542,000
Net Income From Continuing And Discontinued Operation $-18,214,000 $-29,397,000 $-17,347,000 $-20,542,000
Total Operating Income As Reported $-26,748,000 $-28,107,000 $-18,665,000 $-21,193,000
Net Income Common Stockholders $-18,214,000 $-29,397,000 $-17,347,000 $-20,542,000
Net Income $-18,214,000 $-29,397,000 $-17,347,000 $-20,542,000
Net Income Including Noncontrolling Interests $-18,214,000 $-29,397,000 $-17,347,000 $-20,542,000
Net Income Continuous Operations $-18,214,000 $-29,397,000 $-17,347,000 $-20,542,000
Pretax Income $-18,214,000 $-29,397,000 $-17,347,000 $-20,542,000
Interest Income Non Operating $1,375,000 $747,000 $1,318,000 $654,000
Operating Income $-26,748,000 $-28,107,000 $-18,665,000 $-21,193,000
Per Share
Diluted EPS $-3.26 $-11.41 $-6.74 $-7.98
Basic EPS $-2.46 $-11.41 $-6.74 $-7.98
Other
Tax Effect Of Unusual Items $0 $0 $0 $0
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $-26,653,000 $-28,012,000 $-17,252,000 $-20,454,000
Reconciled Depreciation $95,000 $95,000 $95,000 $85,000
EBITDA (Bullshit earnings) $-26,653,000 $-28,012,000 $-17,252,000 $-20,454,000
EBIT $-26,748,000 $-28,107,000 $-17,347,000 $-20,539,000
Diluted Average Shares $7,783,182 $2,575,462 $2,575,462 $2,575,462
Basic Average Shares $7,404,065 $2,575,462 $2,575,462 $2,575,462
Diluted NI Availto Com Stockholders $-18,214,000 $-29,397,000 $-17,347,000 $-20,542,000
Research And Development $18,011,000 $23,650,000 $15,866,000 $18,466,000
Selling General And Administration $8,737,000 $4,457,000 $2,799,000 $2,727,000
Other Gand A $8,737,000 $4,457,000 $2,799,000 $2,727,000
Fetched: 2026-07-06
Balance Sheet (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Assets
Net Tangible Assets $20,624,000 $-91,516,000 $-62,506,000 $-45,562,000
Total Assets $32,073,000 $35,199,000 $27,001,000 $45,097,000
Total Non Current Assets $535,000 $3,513,000 $843,000 $988,000
Other Non Current Assets $17,000 $17,000 $17,000 $17,000
Non Current Deferred Assets $0 $2,811,000 - -
Goodwill And Other Intangible Assets $322,000 $385,000 $448,000 $511,000
Other Intangible Assets $322,000 $385,000 $448,000 $511,000
Current Assets $31,538,000 $31,686,000 $26,158,000 $44,109,000
Prepaid Assets $727,000 $72,000 $3,239,000 $370,000
Cash Cash Equivalents And Short Term Investments $30,811,000 $31,614,000 $22,919,000 $43,739,000
Cash And Cash Equivalents $20,734,000 $31,614,000 $22,919,000 $21,489,000
Debt
Total Debt $201,000 $30,563,000 $368,000 $450,000
Long Term Debt And Capital Lease Obligation $85,000 $30,460,000 $275,000 $368,000
Current Debt And Capital Lease Obligation $116,000 $103,000 $93,000 $82,000
Long Term Debt - $30,259,000 - -
Liabilities
Total Liabilities Net Minority Interest $11,127,000 $126,330,000 $89,059,000 $90,148,000
Total Non Current Liabilities Net Minority Interest $85,000 $115,963,000 $85,778,000 $85,871,000
Current Liabilities $11,042,000 $10,367,000 $3,281,000 $4,277,000
Payables And Accrued Expenses $9,629,000 $9,122,000 $2,246,000 $3,517,000
Payables $3,219,000 $2,186,000 $1,611,000 $2,409,000
Accounts Payable $3,219,000 $2,186,000 $1,611,000 $2,409,000
Equity
Common Stock Equity $20,946,000 $-91,131,000 $-62,058,000 $-45,051,000
Total Equity Gross Minority Interest $20,946,000 $-91,131,000 $-62,058,000 $-45,051,000
Stockholders Equity $20,946,000 $-91,131,000 $-62,058,000 $-45,051,000
Gains Losses Not Affecting Retained Earnings $8,000 $0 $0 $-24,000
Other Equity Adjustments $8,000 - - $-24,000
Retained Earnings $-110,450,000 $-92,236,000 $-62,839,000 $-45,492,000
Preferred Securities Outside Stock Equity $0 $85,503,000 $85,503,000 $85,503,000
Other
Ordinary Shares Number $9,381,344 $9,355,542 $9,355,542 $9,355,542
Share Issued $9,381,344 $9,355,542 $9,355,542 $9,355,542
Tangible Book Value $20,624,000 $-91,516,000 $-62,506,000 $-45,562,000
Invested Capital $20,946,000 $-60,872,000 $-62,058,000 $-45,051,000
Working Capital $20,496,000 $21,319,000 $22,877,000 $39,832,000
Capital Lease Obligations $201,000 $304,000 $368,000 $450,000
Total Capitalization $20,946,000 $-60,872,000 $-62,058,000 $-45,051,000
Additional Paid In Capital $131,379,000 $1,103,000 $762,000 $446,000
Capital Stock $9,000 $2,000 $19,000 $19,000
Common Stock $9,000 $2,000 $19,000 $19,000
Long Term Capital Lease Obligation $85,000 $201,000 $275,000 $368,000
Current Capital Lease Obligation $116,000 $103,000 $93,000 $82,000
Pensionand Other Post Retirement Benefit Plans Current $1,297,000 $1,142,000 $942,000 $678,000
Current Accrued Expenses $6,410,000 $6,936,000 $635,000 $1,108,000
Net PPE $196,000 $300,000 $378,000 $460,000
Gross PPE $196,000 $300,000 $378,000 $460,000
Other Properties $196,000 $300,000 $378,000 $460,000
Other Short Term Investments $10,077,000 $0 $0 $22,250,000
Fetched: 2026-07-06
Cash Flow Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Free Cash Flow
Free Cash Flow $-23,499,000 $-18,305,000 $-21,040,000 $-17,916,000
Operating Activities
Operating Cash Flow $-23,499,000 $-18,305,000 $-21,040,000 $-17,866,000
Cash Flow From Continuing Operating Activities $-23,499,000 $-18,305,000 $-21,040,000 $-17,866,000
Investing Activities
Investing Cash Flow $-10,084,000 $0 $22,468,000 $-22,000,000
Cash Flow From Continuing Investing Activities $-10,084,000 $0 $22,468,000 $-22,000,000
Capital Expenditure - - - $-50,000
Financing Activities
Issuance Of Capital Stock $532,000 $5,000 $2,000 $4,000
Financing Cash Flow $22,703,000 $27,000,000 $2,000 $4,000
Cash Flow From Continuing Financing Activities $22,703,000 $27,000,000 $2,000 $4,000
Net Other Financing Charges $22,171,000 $-1,303,000 - -
Net Common Stock Issuance $532,000 $5,000 $2,000 $4,000
Common Stock Issuance $532,000 $5,000 $2,000 $4,000
Other
Issuance Of Debt $0 $28,298,000 - -
End Cash Position $20,734,000 $31,614,000 $22,919,000 $21,489,000
Beginning Cash Position $31,614,000 $22,919,000 $21,489,000 $61,351,000
Changes In Cash $-10,880,000 $8,695,000 $1,430,000 $-39,862,000
Net Issuance Payments Of Debt $0 $28,298,000 - -
Net Long Term Debt Issuance $0 $28,298,000 - -
Long Term Debt Issuance $0 $28,298,000 - -
Net Investment Purchase And Sale $-10,084,000 $0 $22,468,000 $-21,950,000
Sale Of Investment $21,402,000 $0 $22,468,000 $22,045,000
Purchase Of Investment $-31,486,000 $0 $0 $-43,995,000
Change In Working Capital $508,000 $8,641,000 $-3,959,000 $2,666,000
Change In Other Current Liabilities $-103,000 $-93,000 $-82,000 $-7,000
Change In Payables And Accrued Expense $919,000 $5,567,000 $-1,008,000 $2,195,000
Change In Prepaid Assets $-308,000 $3,167,000 $-2,869,000 $478,000
Other Non Cash Items $723,000 $230,000 $51,000 $34,000
Stock Based Compensation $1,399,000 $319,000 $314,000 $246,000
Unrealized Gain Loss On Investment Securities $-7,810,000 $1,807,000 - -
Amortization Of Securities $-200,000 $0 $-194,000 $-355,000
Depreciation Amortization Depletion $95,000 $95,000 $95,000 $85,000
Depreciation And Amortization $95,000 $95,000 $95,000 $85,000
Net Income From Continuing Operations $-18,214,000 $-29,397,000 $-17,347,000 $-20,542,000
Net PPE Purchase And Sale - - $0 $-50,000
Purchase Of PPE - - $0 $-50,000
Fetched: 2026-07-06